Fintech– 0

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-

Globenewswire·March 25, 2026 at 11:30 AM

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist....

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

EU Auditor Seeks Reforms for Cross-Border Services
PYMNTS
Stablecoin Regulations Focus on Wallets for Adoption
PYMNTS
Crypto market structure bill faces fractured industry reaction
CoinDesk
Platforms Restrict AI Agent Access
PYMNTS

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-

EU Auditor Seeks Reforms for Cross-Border Services

Stablecoin Regulations Focus on Wallets for Adoption

Crypto market structure bill faces fractured industry reaction

Platforms Restrict AI Agent Access